Table 1. Demographic and Clinical Characteristics of Patients With Advanced Melanoma.
| Characteristic | Patients, No. (%) | |
|---|---|---|
| Female (n = 387) | Male (n = 982) | |
| Immune checkpoint inhibitors | ||
| Anti–PD-1 therapy | 347 (89.7) | 857 (87.3) |
| Nivolumab plus ipilimumab combination therapy | 40 (10.3) | 125 (12.7) |
| History of ipilimumab | ||
| Yes | 153 (39.5) | 374 (38.1) |
| No | 234 (60.5) | 608 (61.9) |
| Age at index time (administration of the immunotherapy), y | ||
| <70 | 109 (28.2) | 276 (28.1) |
| 70-79 | 151 (39.0) | 407 (41.4) |
| ≥80 | 127 (32.8) | 299 (30.4) |
| Year of diagnosis | ||
| 1991-2000 | 28 (7.2) | 80 (8.1) |
| 2001-2005 | 47 (12.1) | 132 (13.4) |
| 2006-2010 | 96 (24.8) | 236 (24.0) |
| 2011-2015 | 216 (55.8) | 534 (54.4) |
| Autoimmune disease diagnosis | ||
| 0 | 320 (82.7) | 884 (90.0) |
| ≥1 | 67 (17.3) | 98 (10.0) |
| Cancer history | ||
| Melanoma only | 193 (49.9) | 449 (45.7) |
| History of other primary cancer | 194 (50.1) | 533 (54.3) |
| Charlson Comorbidity Index | ||
| 0 | 276 (71.3) | 685 (69.8) |
| ≥1 | 111 (28.7) | 297 (30.2) |
| Cancer stage at diagnosis | ||
| 0-II or unknown | 284 (73.4) | 700 (71.3) |
| III | 67 (17.3) | 196 (20.0) |
| IV | 36 (9.3) | 86 (8.8) |
| History of radiotherapy | ||
| No radiotherapy or surgery | 338 (87.3) | 857 (87.3) |
| Radiotherapy and surgery (once each) | 49 (12.7) | 125 (12.7) |
| SEER region | ||
| Northeast | 82 (21.2) | 190 (19.3) |
| South | 81 (20.9) | 203 (20.7) |
| North central | 26 (6.7) | 80 (8.1) |
| West | 198 (51.2) | 509 (51.8) |
| Zip code–level, median (IQR) | ||
| Per capita income, $ | 31 130 (23 773-42 575) | 31 180.5 (24 464-41 622) |
| High school graduate, % | 23.9 (16.6-31.2) | 23.8 (16.4-31.3) |
Abbreviations: PD-1, programmed cell death protein 1; SEER, Surveillance, Epidemiology, and End Results.